1
|
Lucijanic M, Krecak I, Busic I, Atic A, Stojic J, Sabljic A, Soric E, Veic P, Marevic S, Derek L, Mitrovic J, Luksic I. Estimated plasma volume status in COVID-19 patients and its relation to comorbidities and clinical outcomes. J Thromb Thrombolysis 2024; 57:50-57. [PMID: 37572182 DOI: 10.1007/s11239-023-02882-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/05/2023] [Indexed: 08/14/2023]
Abstract
Blood plasma is a large reservoir of circulating mediators of inflammation and its expansion has been associated with unfavorable outcomes in patients with inflammatory and cardiovascular diseases. The aim of this study was to determine clinical and prognostic value of estimated plasma volume status (ePVS) in hospitalized patients with COVID-19. We retrospectively investigated 5871 consecutive COVID-19 patient hospitalized in our tertiary-level institution in period 3/2020-6/2021. ePVS was determined using the Strauss-derived Duarte formula and was correlated with clinical characteristics and unwanted outcomes. Median ePVS was 4.77 dl/g with interquartile range 4.11-5.74. Higher ePVS was significantly associated with older age, female sex, higher comorbidity burden, worse functional status, less severe COVID-19 clinical presentation with lower severity and longer duration of symptoms, but more pronounced inflammatory profile with higher C-reactive protein, interleukin-6 and D-dimer levels (P < 0.05 for all analyses). In the multivariate regression analysis U shaped relationship of ePVS with mortality was revealed, present independently of age, sex, COVID-19 severity and comorbidity burden. In addition, higher ePVS was independently associated with higher tendency for mechanical ventilation, intensive care unit treatment, venous thromboembolism, major bleeding and bacteriemia and lower ePVS was independently associated with tendency for arterial thrombotic events. Higher ePVS, indicative of plasma volume expansion and inflammatory cytokine accumulation, may predispose respiratory deterioration and venous thromboembolism, despite less severe initial clinical presentation. Lower ePVS, indicative of hemoconcentration, may predispose arterial thrombotic events. Both may be associated with higher mortality in hospitalized COVID-19 patients.
Collapse
Affiliation(s)
- Marko Lucijanic
- Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, Zagreb, 10000, Croatia.
- School of Medicine, University of Zagreb, Zagreb, Croatia.
| | - Ivan Krecak
- Internal medicine department, General hospital of Sibenik-Knin county, Sibenik, Croatia
- Faculty of Medicine, University of Rijeka, Rijeka, Croatia
| | - Iva Busic
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Armin Atic
- Nephrology Department, University Hospital Center Zagreb, Zagreb, Croatia
| | - Josip Stojic
- Gastroenterology, Hepatology and Clinical Nutrition Department, University Hospital Dubrava, Zagreb, Croatia
| | - Anica Sabljic
- Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, Zagreb, 10000, Croatia
| | - Ena Soric
- Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, Zagreb, 10000, Croatia
| | - Petra Veic
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Sanja Marevic
- Clinical Department for Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia
| | - Lovorka Derek
- Clinical Department for Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia
| | - Josko Mitrovic
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Clinical Immunology, Allergology and Rheumatology department, University hospital Dubrava, Zagreb, Croatia
- Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
| | - Ivica Luksic
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Maxillofacial surgery Department, University Hospital Dubrava, Zagreb, Croatia
| |
Collapse
|
2
|
Lucijanic M, Busic N, Stojic J, Barisic-Jaman M, Zagorec N, Lazibat K, Pasaric A, Vrkljan Vuk A, Durlen I, Mitrovic J, Luksic I, Barsic B. Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate. Expert Opin Drug Saf 2023; 22:1265-1270. [PMID: 37417704 DOI: 10.1080/14740338.2023.2234821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Accepted: 05/23/2023] [Indexed: 07/08/2023]
Abstract
BACKGROUND There are uncertainties regarding associations of prior proton pump inhibitor (PPI) use with susceptibility for COVID-19 and risks associated with SARS-CoV-2 infection. We aimed to evaluate the associations of prior PPI use with outcomes in hospitalized patients with COVID-19. RESEARCH DESIGN AND METHODS We have retrospectively evaluated a total of 5959 consecutively hospitalized patients with COVID-19 from a tertiary-level institution in the period 3/2020-6/2021. Associations of prior PPI use with outcomes of in-hospital mortality, mechanical ventilation, intensive care unit stay, venous thromboembolism, arterial thrombosis, major bleeding, bacteremia, and Clostridioides difficile infection (C. diff.) were evaluated in entire and case-matched cohorts. RESULTS Among 5959 evaluated patients, there were 1967 (33%) PPI users. In an entire cohort, prior PPI use was associated with higher in-hospital mortality and higher occurrence of C. diff. Association of prior PPI use with mortality diminished, whereas association with C. diff. persisted after multivariable adjustments. In a matched cohort, prior PPI use was associated only with higher risk of C. diff. but not other outcomes in line with multivariable analysis. CONCLUSIONS Although prior PPI use might not have a significant impact on clinical course and mortality of SARS-CoV-2 infection, it may predispose patients to the development of complications like higher occurrence of C. diff. and thus substantially impact the course of treatment.
Collapse
Affiliation(s)
- Marko Lucijanic
- Hematology Department, University Hospital Dubrava, Zagreb, Croatia
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Nikolina Busic
- Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia
| | - Josip Stojic
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Zagreb, Croatia
| | - Mislav Barisic-Jaman
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Zagreb, Croatia
| | - Nikola Zagorec
- Nephrology Department, University Hospital Dubrava, Zagreb, Croatia
| | - Karla Lazibat
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Antica Pasaric
- Clinical Immunology, Allergology and Rheumatology Department, University Hospital Dubrava, Zagreb, Croatia
| | | | - Ivan Durlen
- Nephrology Department, University Hospital Dubrava, Zagreb, Croatia
| | - Josko Mitrovic
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia
- Clinical Immunology, Allergology and Rheumatology Department, University Hospital Dubrava, Zagreb, Croatia
| | - Ivica Luksic
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Maxillofacial Surgery Department, University Hospital Dubrava, Zagreb, Croatia
| | - Bruno Barsic
- School of Medicine, University of Zagreb, Zagreb, Croatia
| |
Collapse
|
3
|
Lucijanic M, Marelic D, Stojic J, Markovic I, Sedlic F, Kralj I, Rucevic D, Busic N, Javor P, Lucijanic T, Mitrovic J, Luksic I. Predictors of prolonged hospitalization of COVID-19 patients. Eur Geriatr Med 2023:10.1007/s41999-023-00787-w. [PMID: 37103661 PMCID: PMC10133912 DOI: 10.1007/s41999-023-00787-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2023] [Accepted: 04/11/2023] [Indexed: 04/28/2023]
Abstract
PURPOSE Despite the importance of hospital bed network during the pandemic, there are scarce data available regarding factors predictive of prolonged length of hospitalization of COVID-19 patients. METHODS We retrospectively analyzed a total of 5959 consecutive hospitalized COVID-19 patients in period 3/2020-6/2021 from a single tertiary-level institution. Prolonged hospitalization was defined as hospital stay > 21 days to account for mandatory isolation period in immunocompromised patients. RESULTS Median length of hospital stay was 10 days. A total of 799 (13.4%) patients required prolonged hospitalization. Factors that remained independently associated with prolonged hospitalization in multivariate analysis were severe or critical COVID-19 and worse functional status at the time of hospital admission, referral from other institutions, acute neurological, acute surgical and social indications for admission vs admission indication of COVID-19 pneumonia, obesity, chronic liver disease, hematological malignancy, transplanted organ, occurrence of venous thromboembolism, occurrence of bacterial sepsis and occurrence of Clostridioides difficile infection during hospitalization. Patients requiring prolonged hospitalization experienced higher post-hospital discharge mortality (HR = 2.87, P < 0.001). CONCLUSIONS Not only severity of COVID-19 clinical presentation but also worse functional status, referral from other hospitals, certain indications for admission, certain chronic comorbidities, and complications that arise during hospital stay independently reflect on the need of prolonged hospitalization. Development of specific measures aimed at improvement of functional status and prevention of complications might reduce the length of hospitalization.
Collapse
Affiliation(s)
- Marko Lucijanic
- Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
- School of Medicine, University of Zagreb, Zagreb, Croatia.
| | | | - Josip Stojic
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Zagreb, Croatia
| | - Ivan Markovic
- Special Hospital for Pulmonary Diseases, Zagreb, Croatia
| | - Filip Sedlic
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Department of Oncology, Division of Pathophysiology and Experimental Oncology, University Hospital Center Zagreb, Zagreb, Croatia
| | - Ivan Kralj
- Internal Medicine Department, General Hospital Sisak, Sisak, Croatia
| | - Davor Rucevic
- Intensive Care Unit Department, University Hospital Dubrava, Zagreb, Croatia
| | - Niksa Busic
- Cardiology Department, University Hospital Dubrava, Zagreb, Croatia
| | - Patrik Javor
- Faculty of Medicine, University of Rijeka, Rijeka, Croatia
| | - Tomo Lucijanic
- Endocrinology Department, University Hospital Dubrava, Zagreb, Croatia
- Primary Respiratory and Intensive Care Center, University Hospital Dubrava, Zagreb, Croatia
| | - Josko Mitrovic
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Clinical Immunology, Allergology and Rheumatology Department, University Hospital Dubrava, Zagreb, Croatia
| | - Ivica Luksic
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Primary Respiratory and Intensive Care Center, University Hospital Dubrava, Zagreb, Croatia
- Maxillofacial Surgery Department, University Hospital Dubrava, Zagreb, Croatia
| |
Collapse
|
4
|
Bistrovic P, Sabljic A, Kovacevic I, Cikara T, Keres T, Lucijanic T, Mitrovic J, Delic-Brkljacic D, Manola S, Lucijanic M. Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients - A retrospective cohort study on 5392 patients from a tertiary centre. Int J Cardiol 2023; 372:144-149. [PMID: 36471534 PMCID: PMC9701577 DOI: 10.1016/j.ijcard.2022.11.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Accepted: 11/24/2022] [Indexed: 11/29/2022]
Abstract
INTRODUCTION There are conflicting data on prior oral-anticoagulant (OAC) use and outcomes of hospitalized COVID-19 patients. Due to uncertainties regarding associated risks with the prior OAC use, we have investigated this issue in a large cohort of hospitalized COVID-19 patients from our institution. METHODS We have retrospectively evaluated a total of 5392 consecutive COVID-19 patients hospitalized in our tertiary center institution in period 3/2020 to 6/2021. Majority of patients received low-molecular-weight-heparin thromboprophylaxis and corticosteroids during hospitalization. Patients' characteristics and clinical outcomes were documented as a part of a hospital registry project and were evaluated according to the prior non-OAC, warfarin and direct oral anticoagulants (DOAC) use. RESULTS Median age was 72 years, median Charlson comorbidity index (CCI) was 4 points. There were 56.2% male patients. Majority of patients had severe (70.5%) or critical (15.8%) COVID-19 on admission. A total of 84.8% patients did not receive prior OAC, 9% were previously anticoagulated with warfarin and 6.2% were previously anticoagulated with DOACs. In the multivariate regression analyses, prior warfarin use was associated increased in-hospital mortality (OR 1.24, P = 0.048) independently of older age (OR 2.12, P < 0.001), male sex (OR 1.27, P < 0.001), higher CCI (OR 1.26, P < 0.001) and severe or critical COVID-19 on admission (OR 22.66, P < 0.001). Prior DOAC use was associated with higher occurrence of major bleeding (OR 1.72, P = 0.045) independently of higher CCI (OR 1.08, P = 0.017). CONCLUSION Prior OAC use could be associated with worse clinical outcomes during COVID-19 hospitalization. These phenomena might be OAC type specific and persist after multivariate adjustments.
Collapse
Affiliation(s)
- Petra Bistrovic
- Cardiology department, Clinical Hospital Dubrava, Zagreb, Croatia
| | - Anica Sabljic
- Hematology Department, Clinical Hospital Dubrava, Zagreb, Croatia
| | - Ivona Kovacevic
- Pulmology Department, Clinical Hospital Dubrava, Zagreb, Croatia
| | - Tomislav Cikara
- Cardiology department, Clinical Hospital Dubrava, Zagreb, Croatia
| | - Tatjana Keres
- Intensive Care Department, Clinical Hospital Dubrava, Zagreb, Croatia
| | - Tomo Lucijanic
- Endocrinology, Diabetology and Metabolic Disease Department, Clinical Hospital Dubrava,Primary respiratory and intensive care center, Clinical Hospital Dubrava, Zagreb, Croatia
| | - Josko Mitrovic
- University of Zagreb, School of Medicine,Rheumatology, Immunology and Allergology Department, Clinical Hospital Dubrava
| | - Diana Delic-Brkljacic
- University of Zagreb, School of Medicine,Cardiology department, Clinical Hospital Center Sisters of Mercy, Zagreb, Croatia
| | - Sime Manola
- Cardiology department, Clinical Hospital Dubrava, Zagreb, Croatia,University of Zagreb, School of Medicine
| | - Marko Lucijanic
- Hematology Department, Clinical Hospital Dubrava, Zagreb, Croatia; University of Zagreb, School of Medicine.
| |
Collapse
|
5
|
Lucijanic M, Cikara T, Bistrovic P, Papic I, Hadziabdic MO, Busic N, Lackovic M, Cesar N, Koscak V, Mitrovic J, Barsic B, Lucijanic T. Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis. J Infect 2022; 85:174-211. [PMID: 35513188 PMCID: PMC9060712 DOI: 10.1016/j.jinf.2022.04.045] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Revised: 04/28/2022] [Accepted: 04/29/2022] [Indexed: 12/11/2022]
Affiliation(s)
- Marko Lucijanic
- Hematology Department, University Hospital Dubrava, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia.
| | - Tomislav Cikara
- Cardiology Department, University Hospital Dubrava, Zagreb, Croatia
| | - Petra Bistrovic
- Cardiology Department, University Hospital Dubrava, Zagreb, Croatia
| | - Ivan Papic
- Pharmacy Deaprtment, University Hospital Dubrava, Zagreb, Croatia
| | - Maja Ortner Hadziabdic
- Centre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
| | - Nikolina Busic
- Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia
| | - Marina Lackovic
- Quality Department, University Hospital Dubrava, Zagreb, Croatia
| | - Natalia Cesar
- Quality Department, University Hospital Dubrava, Zagreb, Croatia
| | - Valentina Koscak
- Quality Department, University Hospital Dubrava, Zagreb, Croatia
| | - Josko Mitrovic
- University of Zagreb School of Medicine, Zagreb, Croatia; Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia; Clinical Immunology, Allergology and Rheumatology department, University hospital Dubrava, Zagreb, Croatia
| | - Bruno Barsic
- University of Zagreb School of Medicine, Zagreb, Croatia; Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia
| | - Tomo Lucijanic
- Endocrinology Department, University Hospital Dubrava, Zagreb, Croatia
| |
Collapse
|
6
|
Sredoja Tisma V, Bulimbasic S, Galesic Ljubanovic D, Galesic K, Morovic-Vergles J, Mitrovic J, Uchida K, Tatzber F, Zarkovic N, Jaganjac M. The Onset of Systemic Oxidative Stress Associated with the Accumulation of Lipid Peroxidation Product Acrolein in the Skin of Patients with Small-Vessel Vasculitis. Molecules 2021; 26:molecules26082344. [PMID: 33920659 PMCID: PMC8073584 DOI: 10.3390/molecules26082344] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 04/02/2021] [Accepted: 04/13/2021] [Indexed: 12/11/2022] Open
Abstract
Small-vessel vasculitis (SVV) is the inflammation of the vessel wall that can result in hemorrhage and/or ischemia. Among the histological findings in SVV are increased infiltrating neutrophils, which, due to their oxidative burst and myeloperoxidase activity, release excessive reactive oxygen species, triggering a chain reaction of lipid peroxidation and yielding reactive aldehydes such as acrolein. The implication of oxidative stress in the pathogenesis of SVV was studied, focusing on acrolein immunohistochemistry in the affected skin vessels and systemic stress response. Samples from SVV patients and healthy subjects were collected and analyzed for total serum peroxides, total antioxidant capacity, inflammatory and immunological parameters, as well as for the presence of acrolein–protein adducts in the skin tissue specimens. The obtained data showed that systemic redox homeostasis and iron metabolism are altered in SVV patients. Possible biomarkers in the evaluation of oxidative status, disease activity and prevalence were indicated. Furthermore, a strong correlation between the accumulation of acrolein–protein adducts in the skin and the progression of the disease was revealed. Thus, the results of this study demonstrate that SVV is not only associated with systemic oxidative stress but also with tissue-specific oxidative stress that promotes acrolein formation and protein modification correlating with the severity of cutaneous vasculitis.
Collapse
Affiliation(s)
- Vesna Sredoja Tisma
- Polyclinic Department of Dermatology and Venereology, Dubrava University Hospital, 10040 Zagreb, Croatia;
| | - Stela Bulimbasic
- Department of Pathology and Cytology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia;
| | - Danica Galesic Ljubanovic
- Department of Pathology, School of Medicine Zagreb, University of Zagreb, 10000 Zagreb, Croatia;
- Department of Nephropathology and Electron Microscopy, Dubrava University Hospital, 10040 Zagreb, Croatia
| | - Kresimir Galesic
- Division of Nephrology, Department of Internal Medicine, Dubrava University Hospital, University of Zagreb School of Medicine, 10040 Zagreb, Croatia;
| | - Jadranka Morovic-Vergles
- Division of Clinical Immunology, Allergology and Rheumatology, Department of Internal Medicine, Dubrava University Hospital, University of Zagreb School of Medicine, 10040 Zagreb, Croatia; (J.M.-V.); (J.M.)
| | - Josko Mitrovic
- Division of Clinical Immunology, Allergology and Rheumatology, Department of Internal Medicine, Dubrava University Hospital, University of Zagreb School of Medicine, 10040 Zagreb, Croatia; (J.M.-V.); (J.M.)
| | - Koji Uchida
- Laboratory of Food and Biodynamics, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan;
| | | | - Neven Zarkovic
- Laboratory for Oxidative Stress, Division of Molecular Medicine Rudjer Boskovic Institute, 10000 Zagreb, Croatia;
| | - Morana Jaganjac
- Laboratory for Oxidative Stress, Division of Molecular Medicine Rudjer Boskovic Institute, 10000 Zagreb, Croatia;
- Correspondence: ; Tel.: +385-1456-1017
| |
Collapse
|
7
|
Puksic S, Mitrovic J, Culo MI, Zivkovic M, Orehovec B, Lucijanic M, Bobek D, Morovic-Vergles J. THU0573 YOGA LEADS TO SUSTAINED IMPROVEMENT IN FATIGUE AND MOOD IN RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Rheumatoid arthritis (RA) patients experience reduced health-related quality of life (HRQOL). Previous studies suggest that yoga, a mind-body practice, can improve physical and mental health but it has not been extensively studied in RA.Objectives:To investigate the effect of yoga on HRQOL and secondary on fatigue, anxiety, depression and disease activity in RA patientsMethods:43 RA patients (mean (SD) age 55 (10) years, median (IQR) disease duration 5 (3,8) years, 93% female), stable on standard pharmacological treatment and DAS28CRP < 5.1 were randomly assigned to 12 weeks yoga intervention (2x/week 90 min; n=22) or arthritis-related educational lectures control (1x/week 60 min; n=21). Yoga based on „Yoga in daily life system“ included asanas, relaxation, pranayama and meditation. Study evaluations at baseline, post-intervention and 3-month follow-up included The Short Form-36 (SF-36) scores for Physical Component Summary (PCS) and Mental Component Summary (MCS), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Hospital Anxiety and Depression scale (HADS) and Disease Activity Score-28CRP (DAS28CRP) questionnaires. Data were presented as change from baseline to each time point. Between group differences were analyzed using the t-test for normally and Mann-Whitney U test for non-normally distributed variables. P values <0.05 were considered statistically significant.Results:35 patients (17 = intervention, 18 = control group) completed the trial period. Significant improvement in FACIT-F (p=0.013), HADS anxiety (p=0.047) and HADS depression (p=0.004) was found in yoga group compared to control at post-intervention and maintained at follow-up (p=0.025, p=0.02 and p=0.045, respectively). There was no significant difference found between groups for SF-36 MCS, PCS and DAS28CRP at all time points (all p>0.05). No serious adverse events were observed during trial period.Conclusion:Although no change in SF-36 scores and disease activity was observed, yoga practice produced significant and sustained improvement in fatigue and mood which strongly account for decreased life quality in RA. Despite limitations our findings suggest that yoga may be of benefit in management of RA patients.Table.Changes in outcomesN= 37 (postintervention)N= 35 (follow-up)VariablesBaseline mean (SD)Change from baseline (95%CI)Difference between groups(95%CI, p-value)Change from baseline (95%CI)Difference between groups(95%CI, p-value)FACIT-F(0-52)Yoga 33.89 (10.77)Control 35.37 (9.3)4.18(-0.26,8.61)-2.17(-5.58,1.25)6.66(1.53,11.78)p= 0.0133.29(-1.23,7.82)-3.33(-7.27,0.61)6.63(0.85,12.4)p=0.025HADS-A(0-21)Yoga 7.39 (3.72)Control 6.89 (2.86)-1.94(-3.28,-0.6)0.056(-1.39,1.51)-1.83(-3.64,-0.024)p= 0.047-2.24(-3.63,-0.84)0.17(-1.38,1.71)-2.4(-4.4,-0.04)p=0.02HADS-D(0-21)Yoga 5.11 (3.03)Control 5.0 (1.82)-1.06(-1.92,-0.2)0.83(-0.06,1.72)-1.73(-2.88,-0.58)p= 0.004-0.2(-1.1,0.63)0.94(0.12,1.77)-1.18(-2.33,-0.03)p=0.045SF-36:MCS(0-100)Yoga 49.49 (11.99)Control 49.71 (8.99)2.97(-4.15,10.09)-1.59(-7.51,4.33)3.86(-4.66,12.33)p= 0.3661.25(-3.62,6.12)-0.45(-5.56,4.65)1.7(-5.09,8.49)p=0.618SF-36:PCS(0-100)Yoga 52.57 (10.11)Control 48.30 (9.76)0.44(-3.13,4.02)-1.16(-4.81,2.48)1.61(-3.31,6.53)p= 0.511-1.54(-5.44,2.35)0.35(-3.21,3.92)-1.9(-6.98,3.18)p=0.453DAS28CRPYoga 2.32 (0.81)Control 2.91 (0.84)-0.0024(-0.42,0.42)-0.096(-0.45,0.26)0.093(-0.44,0.63)p=0.7240.11(-0.43,0.66)-0.54(-0.92,-0.17)0.66(0.02,1.3)p=0.092Disclosure of Interests:Silva Puksic: None declared, Josko Mitrovic: None declared, Melanie-Ivana Culo: None declared, Marcela Zivkovic: None declared, Biserka Orehovec: None declared, Marko Lucijanic: None declared, Dubravka Bobek: None declared, Jadranka Morovic-Vergles Speakers bureau: Abbvie., Roche, MSD, Eli Lilly, Pfizer, Mylan, Amgen, Fresenius Kabi
Collapse
|
8
|
Mitrovic J. Modern Drying Technology, Product Quality and Formulation, Vol. 3. Von E. Tsotsas, A. S. Mujumdar (Eds.). CHEM-ING-TECH 2012. [DOI: 10.1002/cite.201290125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
9
|
Mitrovic J. Modern Drying Technology - Vol. 2: Experimental Techniques. Von E. Tsotsas, A.S. Mujumdar. CHEM-ING-TECH 2012. [DOI: 10.1002/cite.201290028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
10
|
|
11
|
|
12
|
Romic Z, Derek L, Burek V, Unic A, Serdar T, Marijancevic D, Morovic-Vergles J, Mitrovic J, Petrovecki M. Anti-cyclic citrullinated peptide and rheumatoid factor in HIV positive patients. Rheumatol Int 2010; 31:1607-10. [DOI: 10.1007/s00296-010-1539-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2010] [Accepted: 05/16/2010] [Indexed: 10/19/2022]
|
13
|
|
14
|
|
15
|
|
16
|
Nedeljkovic J, Mitrovic J, Jovanovic T. Influenza surveillance in Serbia: use of rapid cell culture assay. J Clin Virol 2006. [DOI: 10.1016/s1386-6532(06)80823-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
|
18
|
Bajcetic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R, Gorodischer R. Off label and unlicensed drugs use in paediatric cardiology. Eur J Clin Pharmacol 2005; 61:775-9. [PMID: 16151762 DOI: 10.1007/s00228-005-0981-y] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2004] [Accepted: 07/07/2005] [Indexed: 11/26/2022]
Abstract
OBJECTIVES The use of drugs in an off label or unlicensed manner to treat children is a widespread phenomenon in Europe and the United States. The incidence of unlicensed and off label prescribing in paediatric cardiology practice has not been studied to date. This study was designed to assess the extent and nature of off label and unlicensed drug use in paediatric cardiology inpatients. METHODS In a prospective study, drug prescriptions in a paediatric cardiology ward were reviewed during a 2-year period. Data were collected and analyzed by special software created for this purpose. RESULTS The children (n = 544) studied varied in age from 4 h to 18 years. One or more off label and unlicensed prescriptions were given to 414 (76%) patients. Of the 2,130 prescriptions given during the 2-year period, more than one-half were unlicensed (11%) or off label (47%). While children aged 2-11 years received most of the unlicensed drug prescriptions (17%), neonates, who did not receive unlicensed drugs, led (64%) in the use of off label drugs. CONCLUSIONS. This study showed that the problem of off label and unlicensed drug use also exists in paediatric cardiology. The findings imply that the phenomenon of off label and unlicensed use of drugs in children can be correlated with the deficiency of paediatric drug formulations on the global market and insufficient data from clinical studies which must be performed to confirm the efficacy and safety of drugs in the paediatric population. Therefore, efforts to improve paediatric labelling are important and need the full support of all involved.
Collapse
Affiliation(s)
- M Bajcetic
- Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, P.O. Box 840, 11129, Belgrade, Serbia and Montenegro.
| | | | | | | | | | | | | |
Collapse
|
19
|
|
20
|
|
21
|
|
22
|
Mitrovic J. Kondensation von Dampfgemischen. CHEM-ING-TECH 1995. [DOI: 10.1002/cite.330670943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|